Venture Houston 2018
Skip Content

8 January 2018

KBP kicks back with $76m

KBP Biosciences, which is developing drugs for disease areas of unmet need, raised the series A funds from investors including Ping An Ventures.

Author: Callum Cyrus, Reporter

US-based biopharmaceutical developer KBP Biosciences closed a $76m series A round backed by Ping An Ventures, a corporate venturing subsidiary of insurance group Ping An, on Friday.